WVE-006
Alpha-1 Antitrypsin Deficiency (AATD)
Phase 1/2Active - INHALE trial; Accelerating regulatory engagement
Key Facts
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
Phase
Phase 1/2
Status
Active - INHALE trial; Accelerating regulatory engagement
Company
About WaVe Life Sciences
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Its core strategy is built on the PRISM® platform, a toolkit for designing and developing stereopure oligonucleotides, including RNA editing and silencing therapies. The company is rapidly advancing a diversified pipeline, with key programs like WVE-006 for Alpha-1 antitrypsin deficiency and WVE-007 (INHBE siRNA) for obesity generating significant clinical interest. Wave is strategically positioning itself at the forefront of next-generation genetic medicines.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BEAM-302 | Beam Therapeutics | Preclinical |
| INBRX-101 | Inhibrx Biosciences | Phase 2 |
| Glassia® (IV AAT) | Kamada | Approved |
| Inhaled AAT (KMA-001) | Kamada | Phase 3 |
| GalNAc Program (SERPINA1 target) | Korro Bio | Discovery |
| Unnamed AATD Program | AlveoGene | Pre-clinical |